Low Molecular Weight Fucoidan Suppresses Ferroptosis in Pulmonary Fibrosis

Study Background and Research Question

Pulmonary fibrosis (PF) is a debilitating and progressive interstitial lung disease with limited therapeutic options and a high mortality rate. The global burden of PF is rising, increasing from 1.4 million cases in 2015 to a projected 1.8 million by 2025, with similar trends observed in China (source: paper). Current pharmacological interventions, such as pirfenidone and nidanib, offer only partial efficacy and are associated with notable side effects, underlining the urgent need for novel therapeutic strategies. Recent research has identified ferroptosis—a regulated, iron-dependent form of cell death driven by lipid peroxidation and reactive oxygen species (ROS)—as a key contributor to the pathogenesis of PF, particularly through the loss of alveolar epithelial cell (AEC II) viability (source: paper). The primary research question addressed in the referenced study is whether low molecular weight fucoidan (LMWF), a sulfated polysaccharide derived from Laminaria japonica, can attenuate pulmonary fibrosis by inhibiting ferroptosis and preserving mitochondrial function.

Key Innovation from the Reference Study

The central innovation of this work lies in demonstrating the anti-ferroptotic effect of LMWF in a bleomycin-induced mouse model of PF. While LMWF’s antioxidant and immunomodulatory properties have previously been described, this study uniquely links its therapeutic potential to the modulation of ferroptosis, mitochondrial membrane potential, and the restoration of glutathione peroxidase 4 (GPX4) expression (source: paper). This mechanistic connection advances understanding of how polysaccharide-based interventions may target and disrupt key pathological processes in fibrotic lung disease.

Methods and Experimental Design Insights

A comprehensive murine PF model was established via intratracheal administration of bleomycin. The experimental groups included a vehicle control, PF model, LMWF treatment, and a group co-treated with erastin (a ferroptosis inducer) to dissect the specific impact of ferroptosis modulation. LMWF was prepared through free radical degradation of Laminaria japonica polysaccharide to ensure a reproducible low molecular weight profile. Pathological features of lung tissue were assessed using hematoxylin and eosin (H&E) and Masson’s trichrome staining, while immunohistochemistry and enzyme-linked immunosorbent assays quantified the expression of fibrosis and ferroptosis markers, including alpha smooth muscle actin, collagen, transforming growth factor beta 1, and GPX4. Flow cytometry was employed to measure ROS levels, apoptosis, and mitochondrial membrane potential in lung tissue. Non-targeted metabolomics based on liquid chromatography–mass spectrometry (LC-MS) was performed to identify metabolic alterations associated with ferroptosis, with metabolite identities confirmed using authentic standards (source: paper).

Core Findings and Why They Matter

LMWF significantly reduced collagen deposition and preserved alveolar architecture, indicating an attenuation of fibrosis. Notably, LMWF-treated mice exhibited decreased ROS and apoptosis rates, as well as restoration of mitochondrial membrane potential—an essential parameter for cellular bioenergetics and viability (source: paper). Prussian blue staining revealed that LMWF mitigated iron accumulation, a hallmark of ferroptosis, and metabolomics analyses highlighted reversals of ferroptosis-linked metabolic disturbances. At the molecular level, LMWF restored GPX4 expression and glutathione levels, both central to ferroptosis defense mechanisms. Compared to the ferroptosis-induced group, LMWF preserved mitochondrial morphology and suppressed cell death pathways linked to mitochondrial dysfunction. These results collectively suggest that targeting ferroptosis and mitochondrial integrity may be a promising approach for PF therapy.

Protocol Parameters

• assay | mitochondrial membrane potential assessment | JC-1 (5,6-dichloro-2-[(E)-3-(5,6-dichloro-1,3-diethylbenzimidazol-3-ium-2-yl)prop-2-enylidene]-1,3-diethylbenzimidazole iodide), 2–10 μM | pulmonary tissue and in vitro AEC II models | enables ratiometric detection of mitochondrial depolarization during ferroptosis and apoptosis | workflow_recommendation
• assay | iron accumulation analysis | Prussian blue staining | murine lung tissue | identifies ferroptosis-driven iron overload | paper
• assay | ROS measurement | DCFDA-based flow cytometry | lung tissue | quantifies oxidative stress associated with ferroptosis | paper
• assay | GPX4 expression quantification | immunohistochemistry/ELISA | lung homogenates | monitors ferroptosis pathway activity | paper

Comparison with Existing Internal Articles

Recent review and protocol articles have emphasized the importance of mitochondrial membrane potential assays, particularly using JC-1, in elucidating mechanisms of apoptosis and ferroptosis in disease models. For example, "Redefining Mitochondrial Membrane Potential Assays" provides actionable guidance for integrating ratiometric fluorescent probes like JC-1 into studies of pulmonary fibrosis and ferroptosis, reinforcing the importance of mitochondrial health as a research focus. Similarly, "JC-1 and the Future of Mitochondrial Membrane Potential Assays" highlights how mitochondrial integrity bridges basic research and translational outcomes in fibrosis and cell death studies. Notably, these internal resources consistently position JC-1 as the benchmark for high-sensitivity, reproducible mitochondrial membrane potential assays, with specific attention to its application in both apoptosis detection and mitochondrial dysfunction research. The current reference study further validates this approach by using mitochondrial membrane potential as a readout for ferroptosis-driven injury and the protective effect of LMWF.

Limitations and Transferability

While the study provides strong evidence for the therapeutic potential of LMWF in inhibiting ferroptosis and ameliorating PF in mice, several limitations warrant consideration. The translation of these findings to human disease contexts remains untested; the murine model, while informative, may not fully recapitulate the complexity of human PF pathogenesis. The precise molecular targets of LMWF within ferroptotic signaling pathways also require further elucidation, and optimal dosing parameters for clinical translation have not been established (source: paper). Additionally, while mitochondrial membrane potential assays are robust indicators of mitochondrial health, technical variability (e.g., dye concentration, incubation timing) can influence results. Protocol optimization, as emphasized in internal articles, is essential for reproducibility.

Research Support Resources

For researchers aiming to investigate mitochondrial membrane potential and apoptosis in models of pulmonary fibrosis, the use of validated fluorescent probes is critical. JC-1 (SKU A3516, 5,6-dichloro-2-[(E)-3-(5,6-dichloro-1,3-diethylbenzimidazol-3-ium-2-yl)prop-2-enylidene]-1,3-diethylbenzimidazole iodide) from APExBIO offers a ratiometric, high-sensitivity assay for detecting changes in mitochondrial integrity. Its established performance in mitochondrial membrane potential assays makes it suitable for apoptosis detection and mitochondrial dysfunction research across diverse cell types, including those relevant to fibrosis and ferroptosis studies (internal article). Storage and usage parameters are detailed in the product dossier to ensure reliability in both short-term and longitudinal experiments.